Showing: 1 - 10 of 23 RESULTS

Enclara Pharmacia Announces the Appointment of Mark Morse as CEO

Enclara Pharmacia, the market leader in comprehensive pharmacy management services to the hospice community, announced today the appointment of Mark Morse as Chief Executive Officer. He will assume day-to-day leadership of Enclara and work in partnership with its current leadership team to help reduce pharmacy costs for hospices, improve patient care, and support caregivers through digital innovation, medication access, clinical care and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201014005070/en/

Mark Morse, Chief Executive Officer, Enclara Pharmacia (Photo: Business Wire)

Mark succeeds Andy Horowitz, Enclara founder and CEO, who made plans to move into a strategic advisor role as part of Humana’s acquisition of the pharmacy services provider in February. In the months since, Horowitz has provided direction and leadership throughout the integration process to help bring the two companies together and ensure a smooth transition. He will continue to act as a strategic advisor as part of the Humana-Enclara agreement, and remain involved in the long-term success of the company.

“A key part of our strategic plan, established when Humana agreed to acquire Enclara, was that I would transition into an advisory role when it made the most sense,” Horowitz said. “I believe we have reached a point where it is time for a new leader to execute on the roadmap we have established. I’m really proud of the entire Enclara team and the company we have built together, and I am confident in how Mark will lead Enclara into the future.”

Before joining Enclara, Morse most recently served as Humana’s vice president of Pharmacy Service Operations, overseeing a team of approximately 3,000 associates in 16 domestic and overseas locations. Under his leadership, Humana was named the best in Mail Order Pharmacy Customer Satisfaction in the J.D. Power U.S. 2020 Pharmacy Study, the third consecutive year Humana received this honor. Throughout his over 30-year career, Morse has also led the strategy and operations for many large-scale sales, systems and customer-focused initiatives.

“Andy and his team have built an amazing company, which serves a critical and noble need in the market and for the patients it serves,” Morse said. “I care deeply about advancing both Enclara’s growth and hospices’ capacity to provide quality end-of-life care. My goal is to leverage Humana’s scale and resources to help Enclara deliver timely and cost-effective pharmacy solutions while maintaining what makes Enclara uniquely Enclara.”

Morse’s previous roles at Humana include serving as practice leader for pharmacy benefit management sales, generating an additional $50M in annual revenue. He was also sales director for national and major accounts. Prior to joining Humana in 2001, Morse spent six years with United Healthcare, serving as the business owner for its consumer portal and operations director for health plan and systems migrations. Morse holds a Bachelor of Science in Management Systems from Rensselear Polytechnic Institute, America’s first technological research university.

About Enclara Pharmacia

Enclara Pharmacia is a national full-service PBM and mail order supplier of medications and clinical services developed specifically for the

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (“SMSNA”). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation (“DV”) study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.  The presentations will take place virtually on November 9, 2020 from 7:00 p.m.9:00 p.m. EST during Session 2 (Androgens and Ejaculation/Orgasm Disorders). 

https://www.smsna.org/V1/2020/program/scientific-program?where_person=44
https://www.smsna.org/V1/2020/program/scientific-program?where_person=42

“We know that while COVID-19 infection rates are comparable between men and women, men are developing severe symptoms and dying at a significant higher rate than women. Furthermore, men with comorbidities commonly associated with lower testosterone are at greater risk for severe disease and death,” said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc.  “The presentation on COVID-19 highlight key clinical evidences suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men. Based on the published data, the use of oral testosterone with the goal of achieving physiological testosterone levels should be evaluated in clinical trials of COVID-19.”

Dr. Anthony DelConte, Chief Medical Director of Lipocine further stated, “TLANDO will be the first oral testosterone for treatment hypogonadism without titration requirement. It is expected to be easy to prescribe and use.” Dr. DelConte added, “The SMSNA presentation on TLANDO highlights the key safety and efficacy data from multiple clinical studies supporting TLANDO’s ability to effectively restore testosterone levels in hypogonadal men without need for any dose adjustment.”

Is Oral Testosterone a Potential Treatment for COVID-19 in Men? (Benjamin J. Bruno et al)

The authors performed a literature search to understand the possible mechanisms and clinical evidence concerning testosterone levels in COVID-19 patients.  A recent clinical study investigating testosterone levels in men with COVID-19 found 80% of men who died due to COVID-19 had low total or bioavailable testosterone levels at the time of hospital admission. Those with severe Acute Respiratory Distress Syndrome (“ARDS”) had acutely depressed total testosterone compared to patients who did not exhibit severe ARDS. The mean total testosterone levels for men who required invasive ventilation was 29 ng/dL (normal range ~300-1100 ng/dL), whereas those who were discharged from the ICU had mean total T of 254 ng/dL at the time of ICU admission.

In comparison to other routes of testosterone administration, oral testosterone therapy may be the most convenient and suitable for acute treatment of COVID-19 in

Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

– Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups –

– Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% observed for 20 mg and 60 mg doses of GB001, respectively; 23% improvement observed in 40 mg group –

– TITAN Study in chronic rhinosinusitis did not meet primary or secondary endpoints –

– Gossamer to hold webcast to discuss trial results at 8:00 am EDT –

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its Phase 2 TITAN trial in patients with chronic rhinosinusitis.

“While we did not achieve statistical significance on the primary endpoint in the LEDA Study, we are encouraged by the consistent results observed for all three doses of once-daily, oral GB001 therapy across the primary and secondary endpoints,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We believe these data provide important information for designing a well-powered Phase 3 program for GB001 in severe asthma. We plan to engage in global regulatory discussions in order to inform our thinking around potential partnerships or strategic alternatives for this program.”

“The results of the robust LEDA Study are meaningful and help us to further understand the DP2 pathway in asthma,” said Bruce Levy, M.D., Chief, Division of Pulmonary and Critical Care Medicine at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. “I believe GB001 as an oral treatment has the potential to serve the high unmet need of patients with uncontrolled severe asthma.”

LEDA Phase 2b Trial Design

The LEDA trial enrolled 480 patients with uncontrolled, moderate-to-severe eosinophilic asthma and assessed the effect of oral GB001 add-on therapy to standard of care over 24 weeks, comparing three dose groups of once-daily, oral GB001 (20 mg, n=120; 40 mg, n=118; and 60 mg, n=122) to placebo (n=120).

The primary endpoint, asthma worsening, included five components and was chosen for its sensitivity in detecting deterioration in clinical outcome measures known to be correlated with exacerbations. A patient was considered to have experienced asthma worsening if they met any of the five components by Week 24. This endpoint has previously been used in the context of steroid withdrawal studies, including a prior Phase 2 trial of GB001.

LEDA Primary and Secondary Endpoint Results

The primary endpoint of the trial was not met, though consistent and meaningful numeric reductions in the odds of asthma worsening as compared to placebo were observed across all GB001 groups: 33% (p=0.1425), 32% (p=0.1482), and 35% (p=0.1086), for the GB001 20 mg, 40 mg, and 60 mg groups, respectively. In addition, statistically significant improvements in the key secondary endpoint of time to first asthma worsening as compared to placebo

Sidero Bioscience Announces Agreement with SRS Life Sciences for Commercialization of BioFe for Iron Deficiency

Sidero Bioscience, LLC, (Hershey, PA) a clinical stage biotechnology company targeting human digestive health, today announces the execution of a term sheet agreement with SRS Life Sciences PTE. LTD, (Singapore) a leading life sciences company. The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.

“This agreement illustrates the excellent partners and licensing opportunities available for our robust and intuitive BioFe technology,” noted Darren Wolfe, Ph.D., President & CEO, Sidero, adding “Iron Deficiency remains a massive global unmet medical need, one that BioFe addresses with natural biology instead of chemicals. We are encouraged by the eagerness of the SRS team to work with us and expect a binding agreement in the near term.”

“At SRS Life Sciences, we exist to change what’s possible for the health of the 6 billion people living in emerging nations. We continuously identify the most pressing unmet healthcare needs so we can be first to deliver products and solutions that lessen the burden of disease,” states Suchet Rastogi, CEO, SRS Life Sciences. Mr. Rastogi continues, “With BioFe, our initial target is to move the needle on the 468 million women suffering from anemia.”

Iron Deficiency (ID), the most common and widespread global nutritional disorder, affects over 2 billion people and causes about 1 million deaths/year (predominantly in Africa/Southeast Asia). The WHO estimates a staggering $2 trillion annual global economic cost due to micronutrient deficiencies, with iron being the most common. ID, which frequently progresses to Iron Deficiency Anemia (IDA), is associated with numerous medical conditions and symptoms, affecting all ages – prenatal to elderly. In the young, ID impedes motor and mental development leading to lifelong physical and cognitive deficiencies. In adults, ID causes fatigue, reduced work capacity, and reduced quality of life among many other symptoms. Iron deficiency is also linked to restless leg syndrome (RLS), hearing deficits, and heart failure and kidney disease morbidity. Significantly, even mild Iron Deficiency leads to decreased physical/athletic performance and also decreased intellectual/cognitive performance.

James Connor, Ph.D., Founder and Chairman of the Sidero Board, states, “In partnership with SRS, we strive to provide a safe, effective, and cost-efficient treatment option for iron deficiency. The SRS health team understands the global impact of ID/IDA and are experts in launching transformational technologies, like BioFe, to fill significant unmet medical needs.”

About Sidero Bioscience

Sidero is advancing disruptive technologies utilizing the patented SiderosorbTM platform that employs nutritional Baker’s yeast, Saccharomyces cerevisiae, to provide therapeutic proteins/complexes to improve human health. BioFeTM is a nutritional yeast strain expressing very high levels of H-Ferritin, FTH1, a natural iron transport and storage protein. An illustrative example of the natural biology of the Ferritin/Iron complex is its presence in human breast milk, providing nursing infants the readily adsorbed iron required for growth and development without gastrointestinal upset. Sidero is currently preparing manuscripts detailing the preclinical and clinical development

Warrnambool Dental, a Top-Rated Dentist Warrnambool, VIC Announces Cosmetic and Dental Implant Treatments

(MENAFN – GetNews)

Warrnambool, VIC – Warrnambool Dental is proud to announce the inclusion of cosmetic and dental implant treatments as part of the dental services that they offer. The new treatment is a welcoming alternative to dentures which can be uncomfortable if worn for long extended periods of time.

‘For the permanent replacement of missing teeth, Warrnambool Dental offers patients an incredibly effective and natural-looking solution. By choosing dental implants in replacing missing teeth, you can restore your dental health by correcting your bite and protecting the integrity of your jawbone and adjacent teeth, said Dr. Nishant Hurria, the spokesperson for the dental practice, regarding their unrivaled services.

There are several causes of tooth loss. It could be decaying teeth, fractured teeth, periodontal disease, or trauma-related accidents. Patients can now get cosmetic and dental implants with the same level of care and quality when they get in touch with Warrnambool Dental.

The dental practice is all about restoring patients’ smiles that will last for years to come. In addition to cosmetic and dental implant treatments, patients can also get general dental and full mouth rehabilitation treatments. The team at Warrnambool Dental is focused on balancing the dental needs and personal goals of their patients.

Smile Makeovers

Dr. Nishant Hurria has a combination of experience, advanced technique, and a good eye for aesthetics to ensure that patients are smiling when they leave his office. The whole practice takes great pride in providing comprehensive dental procedures so that patients are leaving better than when they visited the clinic for the first time.

Full Mouth Rehabilitation

A bad bite, tooth decay, periodontal disease, and more can result in the teeth needing to be repaired or replaced. Dr. Nishant Hurria offers full mouth rehabilitation treatment that helps in restoring smiles with pain-free confidence. The dentist has the training and experience to evaluate and correct issues with bite. Patients can rest easy knowing that they’re working with a  dentist Warrnambool that cares about providing quality dental care and treatment services.

Dental Implants

Patients that have lost their teeth through an accident or periodontal disease can now get in touch with Warrnambool Dental. The teeth that are replaced look and are just as functional as natural teeth. Dr. Nishant Hurria will ensure that the procedure is done safely and efficiently utilizing the best practices.

New Patients are Always Welcome

For patients looking for a reliable family dentist or someone to perform cosmetic procedures, there is an expert team at Warrnambool Dental that is always ready to provide high-quality dental care and treatment services.

Getting the right dentist is imperative for good oral health. Warrnambool Dental has also made it easy to book dental appointments so that patients don’t have to wait for weeks before seeing the right provider. Most insurance plans are accepted so that patients have access to high-quality dental treatment. The team at Warrnambool Dental will ensure that patients are always comfortable and feeling at home whenever they visit their offices.

To get

Braintree Announces Events For Senior Fitness Week

BRAINTREE, MA — The town Department of Elder Affairs has organized two events to help Braintree seniors stay fit and enjoy themselves.

This year, theDepartment of Elder Affairs will be hosting Senior Health and Fitness Week from Oct. 13 to Oct. 20. Events will be held Tuesday through Thursday from 10 a.m. to 12:30 p.m. and 9:30 a.m. to 12:30 p.m., on Friday

All events during Senior Health and Fitness Week will take place outdoors at the Braintree Council on Aging at 71 Cleveland Ave.

“The Department of Elder Affairs, throughout this pandemic, has continued to step out of the box to create programs and offer services for the older adults of our community,” Elder Affairs director Sharmila Biswas said. “This will be a wonderful opportunity for our older adults to spend time outdoors with friends, while maintaining all the COVID-19 safety protocols.”

Events for Senior Health and Fitness Week include cardio strength and flexibility classes, classes on healthy food preparation, outdoor walks and live entertainment. For a full list of the week’s events, click here.

All events are free and open to Braintree seniors, but donations will be accepted.

“We are extremely excited to be able to host Senior Health and Fitness Week in place of our annual Pond Meadow Senior Walk this year,” Mayor Charles Kokoros said in a statement. “Sharmila and the Department of Elder Affairs staff continue to do a great job of planning these activities and programs for residents to enjoy.”

The department is also slated to host an outdoor bingo event at 10 a.m. on Wednesday, Oct. 20. Outdoor bingo will be held at the Braintree Council on Aging.

In compliance with social distancing and COVID-19 regulations, guests are encouraged to begin seating themselves outdoors at 9:30 a.m. prior to the event.

Senior Health and Fitness Week and outdoor bingo are open to all Braintree seniors. Pre-registration is required, and residents can do so by calling the Department of Elder Affairs at 781-848-1963.

This article originally appeared on the Braintree Patch

Source Article

Boris Johnson Announces Three-tier Coronavirus Strategy for England

Tighter restrictions have been confirmed by the Government as the Prime Minister confirmed a ‘three-tier’ system for England to classify the severity of rates of COVID-19.

From Wednesday, regions will be classed as either ‘medium’, ‘high’, or ‘very high’ risk.

The details, announced in the Commons by Boris Johnson, came as the NHS said that Nightingale hospitals in Manchester, Sunderland, and Harrogate were being asked to mobilise in the next few weeks in response to growing rates of SARS-CoV-2 infections in the North West and North East.

Speaking at a Downing Street news briefing earlier, Prof Jonathan Van-Tam, England’s deputy chief medical officer, warned that additional hospital admissions and deaths were now ‘baked in’ as the virus spread from younger to older age groups.

What the Three Tiers Mean

Speaking ahead of his evening televised address to the nation, Mr Johnson said he did not believe another national lockdown was appropriate but that he was not prepared to “let the virus rip”.

The three-tier system would mean:

  • Medium: Covering most of England, national restrictions such as the ‘rule of six’ and the 10pm curfew for pubs, bars, and restaurants would apply

  • High: People in areas including Greater Manchester and Birmingham would be prevented from socialising with other households indoors

  • Very High: People would be banned from socialising with other households both indoors and in private gardens, while bars and pubs would be closed unless they were able to operate as restaurants

The Prime Minister said that agreement had been reached with leaders in Merseyside for the Liverpool city region to move into the ‘very high’ alert level. There, gyms, leisure centres, betting shops and casinos would also be told to close.

Mr Johnson said that discussions were ongoing with other leaders in the North West, North East, and Yorkshire and Humber over lockdown restrictions.

Mr Johnson told the Commons: “They, like us, like everyone in this House, are grappling with very real dilemmas, but we cannot let the NHS fall over.”

He warned MPs that “the weeks and months ahead will continue to be difficult and will test the mettle of this country”.

A debate and a vote on the new restrictions will take place at Westminster. The Government has promised to keep the measures under continual review.

In reply, Labour leader Keir Starmer said it was clear that the country faced a “critical moment” in efforts to contain the SARS-CoV-2 virus.

However, he added: “I’m now deeply sceptical that the Government has actually got a plan to get control of this virus, to protect jobs, or regain public trust.”

Cases of Coronavirus ‘Heating Up’

Illustrating the latest situation this morning with a series of maps and graphs, Prof Van-Tam said latest data showed COVID-19 cases were “heating up” south of the West Midlands and East Midlands.

“It has changed in a matter of just a few days, and that is clearly of concern to me,” he said.

Prof Van-Tam said that while the resurgence of cases in Northern England

Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine

Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced the publication in Nature Medicine of interim findings from its ongoing phase 1 GINAKIT2 clinical trial collaboration with Baylor College of Medicine and Texas Children’s Hospital, in high risk relapsed refractory (R/R) patients with neuroblastoma, a form of childhood cancer.

The interim results demonstrated that expressing the CAR with interlukin-15 (IL-15), a natural protein that supports NKT survival, enhanced the tumor-fighting capabilities and in vivo persistence of autologous NKT cells. Two of three patients studied showed tumor reduction following CAR-NKT infusion: one classified as stable disease and the other as a partial response. Imaging revealed a dramatic reduction in the size and metabolic activity of bone metastases in the patient with the partial response. CAR-NKT cells demonstrated a favorable safety profile and localized to the site of the neuroblastoma tumors.

Kuur is the first company to test CAR-NKT cell therapy in patients. The company’s revolutionary platform engineers CARs on invariant NKT cells, a subset of T lymphocytes. NKT cells represent the next generation of CAR therapy, because this innovative approach harnesses the innate tumor-homing properties of NKT cells, a specialized type of lymphocyte that eliminates tumor-supportive macrophages, activates anti-tumor NK, dendritic and CD8 T cells, and does not induce graft versus host disease when used in an allogeneic setting.

“These results validate the biology of CAR-NKT cells in that they home to tumor and marrow, expand and have tumor killing properties. They also demonstrate safety and enhanced tumor homing capabilities, offering distinct advantages over other cell types for the treatment of solid and hematological tumors,” said Kurt C. Gunter, MD, CMO of Kuur. “Using our novel engineering platform, we have manufactured CAR-NKT cells with high purity and added IL-15 to the CAR construct, which further increases in vivo persistence and anti-tumor activity. We look forward to continuing our research with the experts in cellular and gene therapy at Baylor as we aim to leverage the CAR-NKT cell approach to create more precise and effective therapies for cancer patients, including allogeneic therapies.”

The results published were derived from the three heavily pre-treated, R/R metastatic neuroblastoma patients in dose level 1 (3×106 CAR-NKTs/m2) of the GINAKIT2 clinical study. These data were originally presented at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2020. The trial is currently enrolling at the fourth and highest dose level.

About KUR-501

KUR-501 is an autologous product in which natural killer T (NKT) cells are engineered with a chimeric antigen receptor (CAR) targeting GD2, which is expressed on almost all neuroblastoma tumors. KUR-501 is also designed to address key limitations of current CAR immune cell therapies by secreting the cytokine IL-15, which has been shown in nonclinical studies to increase the persistence of CAR-NKT cells and improve their efficacy within the immunosuppressive tumor microenvironment. KUR-501 is being tested in the phase 1

Dentist North Lakes, Passion Family Dental North Lakes Announces General Dental Treatments in QLD – Press Release

Dentist North Lakes, Passion Family Dental North Lakes Announces General Dental Treatments in QLD

North Lakes, QLD – Getting a dentist that can be trusted with the oral health of the family is always going to be a challenging undertaking. Such a provider could have all the experience in the world but still fails to get along with the patients. Passion Family Dental North Lakes is all about providing compassionate dental care and treatment services for the residents of North Lakes, QLD. The practice was founded on the premise of providing high-quality dental care & treatment services in a safe and comfortable environment. That is why the clinic has decided to announce the reaffirmation of its commitment by providing general dental treatments.

“At Passion Family Dental North Lakes, we are committed to understanding and working together with you to help take control of your oral health. We recognize that some people find going to the North Lakes dentist a daunting experience, our staff has many years of experience and has gained skills in helping nervous patients overcome their fears. You can relax knowing that you are in very caring hands,” said Dr. Sam Ooi, the spokesperson for the dental clinic, regarding their unrivaled staff.

Passion Family Dental North Lake’s sole focus is on providing quality dental care at affordable prices. There is no reason why a patient should have to go through the pain and agony when they can reach out to the clinic for all of their dental treatment needs.

There is no patient that likes to be surprised with a hefty bill at the end of an appointment. That is why the clinic always makes an effort to make the patients aware of the cost of treatment before it can commence. Patients can go through the different prices on their website, depending on the type of treatment that they’re looking for.

For assistance with payment, Passion Family Dental North Lakes offers no-interest plans that patients can take advantage of so that they’re not missing out on high-quality dental treatments.

Searching for a dentist North Lakes has never been easier than with Passion Family Dental North Lakes. All patients have to do is go online and book an appointment. No more waiting for weeks before seeing a dentist. The practice understands that patients have unique needs when it comes to dental care and treatment. They start by listening to the patient while taking into consideration their needs and requirements. Since they have the patients’ best interest at heart, patients can be assured of getting a warm and pleasant dental experience.

However, going to the dentist is not always a pleasant experience. This a fact that Passion Family Dental North Lakes understands all too well. Their staff will go above and beyond to ensure that patients are always comfortable when they visit their clinic. Dr. Sam Ooi will never rush an appointment and will make sure that each patient feels at home when they visit. Patients can expect to be treated with the utmost respect and in a gentle manner.

Visit Passion Family Dental

Warrnambool Dental, a Top-Rated Dentist Warrnambool, VIC Announces Cosmetic and Dental Implant Treatments – Press Release

Warrnambool Dental, a Top-Rated Dentist Warrnambool, VIC Announces Cosmetic and Dental Implant Treatments

Warrnambool, VIC – Warrnambool Dental is proud to announce the inclusion of cosmetic and dental implant treatments as part of the dental services that they offer. The new treatment is a welcoming alternative to dentures which can be uncomfortable if worn for long extended periods of time.

“For the permanent replacement of missing teeth, Warrnambool Dental offers patients an incredibly effective and natural-looking solution. By choosing dental implants in replacing missing teeth, you can restore your dental health by correcting your bite and protecting the integrity of your jawbone and adjacent teeth,” said Dr. Nishant Hurria, the spokesperson for the dental practice, regarding their unrivaled services.

There are several causes of tooth loss. It could be decaying teeth, fractured teeth, periodontal disease, or trauma-related accidents. Patients can now get cosmetic and dental implants with the same level of care and quality when they get in touch with Warrnambool Dental.

The dental practice is all about restoring patients’ smiles that will last for years to come. In addition to cosmetic and dental implant treatments, patients can also get general dental and full mouth rehabilitation treatments. The team at Warrnambool Dental is focused on balancing the dental needs and personal goals of their patients.

Smile Makeovers

Dr. Nishant Hurria has a combination of experience, advanced technique, and a good eye for aesthetics to ensure that patients are smiling when they leave his office. The whole practice takes great pride in providing comprehensive dental procedures so that patients are leaving better than when they visited the clinic for the first time.

Full Mouth Rehabilitation

A bad bite, tooth decay, periodontal disease, and more can result in the teeth needing to be repaired or replaced. Dr. Nishant Hurria offers full mouth rehabilitation treatment that helps in restoring smiles with pain-free confidence. The dentist has the training and experience to evaluate and correct issues with bite. Patients can rest easy knowing that they’re working with a dentist Warrnambool that cares about providing quality dental care and treatment services.

Dental Implants

Patients that have lost their teeth through an accident or periodontal disease can now get in touch with Warrnambool Dental. The teeth that are replaced look and are just as functional as natural teeth. Dr. Nishant Hurria will ensure that the procedure is done safely and efficiently utilizing the best practices.

New Patients are Always Welcome

For patients looking for a reliable family dentist or someone to perform cosmetic procedures, there is an expert team at Warrnambool Dental that is always ready to provide high-quality dental care and treatment services.

Getting the right dentist is imperative for good oral health. Warrnambool Dental has also made it easy to book dental appointments so that patients don’t have to wait for weeks before seeing the right provider. Most insurance plans are accepted so that patients have access to high-quality dental treatment. The team at Warrnambool Dental will ensure that patients are always comfortable and feeling at home whenever they visit their offices.

To get a reliable dentist